Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.

Abstract

BACKGROUND Immunoglobulin (IG) products, including intravenous (IVIG) or subcutaneous (SCIG) immunoglobulins are considered safe and effective for medical therapy; however, a sudden and unexpected increase in thromboembolic events (TE) after administration of certain batches of IVIG products has been attributed to the presence of activated coagulation… (More)
DOI: 10.1159/000440824

Topics

5 Figures and Tables

Slides referencing similar topics